Previstage GCC test for staging patients with colorectal cancer.
The presence of tumor cells in regional lymph nodes is the most important prognostic and predictive marker in staging patients with colorectal cancer. Cancer cells in lymph nodes are associated with a poorer prognosis and an increased risk of recurrent disease. Additionally, nodal metastases identify patients who derive maximum benefit from adjuvant therapy. However, traditional paradigms for staging patients with colorectal cancer underestimate the extent of metastases and patients whose lymph nodes are ostensibly free of tumor cells by histopathology (pN0) have a 25-30% risk of developing recurrent disease, reflected by the presence of occult nodal metastases. These observations underscore the unmet clinical need for molecular approaches to accurately detect metastatic disease and identify patients at risk for disease relapse that could benefit from adjuvant chemotherapy. Detection of disease-specific mRNA targets as prognostic and predictive markers employing quantitative reverse transcription (qRT)-PCR is an emerging technology that has become a benchmark for individualization of patient management. However, to date, applications of qRT-PCR to detecting occult nodal metastases in colorectal cancer have been equivocal, reflecting markers with suboptimal sensitivity and specificity; limitations of utilizing qualitative, rather than quantitative, RT-PCR; and underpowered study designs based on inadequate patient populations. In that context, guanylyl cyclase C (GCC) is the most sensitive and specific biomarker for metastatic colorectal cancer in extra-intestinal tissues. GCC qRT-PCR detects occult metastases in lymph nodes, providing the most powerful independent prognostic information for predicting disease recurrence in pN0 patients in prospective multicenter clinical trials. This technology forms the basis for the Previstagetrade mark GCC Colorectal Cancer Staging Test encompassing a proprietary multiplex qRT-PCR assay compatible with formalin-fixed, paraffin-embedded lymph nodes for detecting occult metastases. Previstage GCC is a new diagnostic tool that may improve the accuracy of staging, prognosis of clinical outcomes and prediction of therapeutic responses to adjuvant therapy, representing a key advance in the management of patients with colorectal cancer.
Mejia
Alex
A
Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 132 South 10th Street, 1170 Main, Philadelphia, PA 19107, USA. alex.mejia@jefferson.edu
Waldmana
Scott A
SA
D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D015179:Colorectal Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000473:pathology*; D006162:Guanylate Cyclase / Q000032:analysis* / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D025202:Molecular Diagnostic Techniques / Q000379:methods*; D009367:Neoplasm Staging
D014408:Biomarkers, Tumor; D006162:Guanylate Cyclase
J Clin Oncol. 2002 Feb 15;20(4):1049-55
11844829
Cancer J. 2003 Jul-Aug;9(4):302-12
12967141
Trends Mol Med. 2003 May;9(5):189-95
12763523
Nat Protoc. 2006;1(3):1559-82
17406449
Int J Colorectal Dis. 2004 Sep;19(5):430-7
14716495
N Engl J Med. 2005 Feb 3;352(5):476-87
15689586
N Engl J Med. 1998 Jul 23;339(4):264-5
9673307
J Clin Oncol. 1998 Aug;16(8):2632-40
9704713
J Clin Oncol. 2002 Oct 15;20(20):4232-41
12377967
Int J Cancer. 2004 Jan 20;108(3):412-7
14648708
Gastroenterology. 2008 May;134(5):1570-95
18384785
Clin Cancer Res. 2006 Aug 1;12(15):4545-52
16899600
Gastroenterol Clin North Am. 2008 Mar;37(1):1-24, v
18313537
Dis Colon Rectum. 1998 Mar;41(3):310-5
9514425
J Clin Oncol. 2005 May 20;23(15):3526-35
15908663
Clin Pharmacol Ther. 2007 Oct;82(4):441-7
17687268
CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308
15537574
J Pathol. 1994 Feb;172(2):183-7
7513353
Hum Pathol. 2005 Feb;36(2):170-9
15754294
J Mol Diagn. 2007 Nov;9(5):563-71
17916603
Pharmacol Rev. 2000 Sep;52(3):375-414
10977868
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14827-32
8962140
Int J Colorectal Dis. 2004 Mar;19(2):87-94
13680284
Ann Surg. 2007 Oct;246(4):568-75; discussion 575-7
17893493
Eur J Surg. 1996 Aug;162(8):637-42
8891622
Dis Colon Rectum. 1999 Feb;42(2):143-54; discussion 154-8
10211489
Ann Surg. 1993 Sep;218(3):270-5; discussion 275-8
8373270
Ann Surg Oncol. 2001 Mar;8(2):158-62
11258781
Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6871s-6s
18006792
Histopathology. 2007 Mar;50(4):453-64
17448021
Dis Colon Rectum. 1998 Oct;41(10):1244-9
9788387
J Clin Oncol. 1994 Apr;12(4):725-9
7512130
J Clin Oncol. 2001 Oct 1;19(19):3951-9
11579116
Strahlenther Onkol. 2004 Apr;180(4):201-8
15057430
Br J Cancer. 1999 Apr;79(11-12):1813-20
10206298
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Ann Surg Oncol. 2006 Nov;13(11):1386-92
17009147
Ann Surg Oncol. 2006 Jun;13(6):823-35
16614884
Gastroenterology. 2008 May;134(5):1296-310
18471507
Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6853s-6s
18006789
N Engl J Med. 1998 Jul 23;339(4):223-8
9673300
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8549-56
16361536
Dis Colon Rectum. 1997 Dec;40(12):1465-71
9407986
Expert Rev Mol Diagn. 2005 Sep;5(5):701-13
16149873
Ann Intern Med. 1999 Dec 7;131(11):805-12
10610624
Oncology. 2006;71(5-6):312-9
17687192
Br J Surg. 2001 Oct;88(10):1307-20
11578283
Dis Colon Rectum. 2004 May;47(5):679-86
15037935
Dig Dis Sci. 2003 Dec;48(12):2284-9
14714614
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
17237035
Cancer. 1994 Feb 1;73(3):563-9
7507795
Dis Colon Rectum. 2003 Feb;46(2):221-31
12576896